

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/002529 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2004/009622

(22) International Filing Date: 29 March 2004 (29.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/458,869 28 March 2003 (28.03.2003) US

(71) Applicant and

(72) Inventor: HIMAWAN, Jeff [US/US]; 7 Calle Mercida,
Talega Complex, San Clemente, CA 92673-6847 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAMILTON,**

Anita, A. [GB/GB]; 130 Kings Gate, Aberdeen, AB15
4EQ (GB). CARR, Francis, J. [GB/GB]; Birchlea, The
Holdings, Balmedie, Aberdeenshire AB23 8XU (GB).


(74) Agents: ANTLER, Adriane, M. et al.; Jones Day, 222
East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: IMMUNOGENICITY-REDUCED ANTI-CR1 ANTIBODY AND COMPOSITIONS AND METHODS OF TREAT-
MENT BASED THEREON



(57) Abstract: The invention provides immuno-
genicity-reduced antibodies or antibody fragments
that bind a human CR1 receptor. The immuno-
genicity-reduced anti-CR1 antibody of the invention
comprises one or more non-human sequences
modified to comprise one or more amino acid
substitutions so that the immunogenicity-reduced
antibody is non-immunogenic or less immunogenic
to a human. The invention also provides bispecific
molecules comprising such an immunogenicity-re-
duced anti-CR1 antibody and an antigen-recognition
portion that binds a pathogen. The invention further
provides methods and compositions for the treatment
of diseases or disorders caused by a blood-borne
immunogenic pathogen using the bispecific molecule
of the invention.

DNA and amino acid sequence of murine B11 V α 2

WO 2005/002529 A2



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*